Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04003610 · ClinicalTrials.gov registry record · Phase 2
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04003610 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 7 participants.
The verdict
NCT04003610, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Gemcitabine
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2021-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04003610
The ClinicalTrials.gov registry entry for NCT04003610 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04003610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04003610 about?
NCT04003610 is a clinical study titled "Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)". The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearran...
What is the current status of trial NCT04003610?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-05-14. Estimated completion is 2021-04-18.
What interventions are being tested in trial NCT04003610?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Gemcitabine (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT04003610?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.